查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864057

溶瘤病毒疗法市场按癌症适应症、病毒类型、给药途径和最终用户划分－2025-2032年全球预测

Oncolytic Virus Therapies Market by Cancer Indication, Virus Type, Administration Route, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，溶瘤病毒疗法市场将成长至 4.4483 亿美元，复合年增长率为 16.34%。

关键市场统计数据
基准年 2024 1.325亿美元
预计年份：2025年 1.5379亿美元
预测年份 2032 4.4483亿美元
复合年增长率 (%) 16.34%

溶瘤病毒疗法的策略架构：聚焦转化潜力、生产实际情况、临床设计要务和生态系统驱动因素

溶瘤病毒疗法处于病毒学、免疫肿瘤学和精准医学快速发展的交叉领域，它提供了一种全新的作用机制，能够选择性地感染并裂解癌细胞，同时刺激抗肿瘤免疫。该领域已从概念验证临床试验发展到病毒基因组、有效载荷和递送系统的复杂设计，旨在拓宽治疗窗口并解决固态肿瘤治疗的可及性难题。随着研发路径的演进，相关人员必须兼顾生物学的复杂性与实际考量，例如可扩展的生产、低温运输物流以及对能够同时反映直接溶瘤效应和下游免疫介导反应的可靠临床终点的需求。

成功的临床转化往往取决于在临床前阶段将机制理解与实用试验设计结合。早期研究的迭代成果已改善了患者选择策略、肿​​瘤内和全身给药方案，以及与查核点抑制剂和其他免疫调节剂的联合治疗。未来的进展需要科学创新和与监管机构的密切合作，从而建立有效的安全监测框架并检验预测疗效和抗药性的生物标记。此外，由公共和私营研究机构、临床试验网络和专业契约製造组织构成的营运基础设施将决定有前景的候选药物从实验室进入大规模队列评估的速度。

肿瘤病毒疗法的未来发展轨迹不仅取决于科学突破，还取决于整个生态系统扩大生产规模、保障病毒载体和原材料供应链以及应对不断变化的医疗和政策环境的能力。积极应对这些转化和营运挑战的相关人员将更有能力将生物学潜力转化为临床可行的治疗方法。

近期技术进步、联合治疗策略、改进的生产流程以及不断变化的法规环境如何重新定义溶瘤病毒的开发和商业化

溶瘤病毒疗法的格局正在转变，重塑竞争格局、临床开发策略和投资重点。病毒工程技术的进步使得载体能够整合调节肿瘤微环境、表达免疫刺激细胞激素以及呈现肿瘤相关抗原的有效载荷，从而增强抗原的传播。这些技术变革与改进的载体设计相辅相成，提高了肿瘤选择性并减少了脱靶亲和性，从而提高了治疗指数，并将潜在适应症扩展到易于治疗的浅表病变之外。

同时，临床策略正从验证单药疗法的疗效转向联合治疗，其中溶瘤病毒与免疫查核点抑制剂、过继性细胞疗法或标靶治疗具有协同作用。这种转变需要更复杂的试验设计和协作网络来检验合理的联合治疗和给药顺序。在营运方面，符合GMP规范的生产和填充流程的改进使得高品质、可重复的病毒药物产品批次得以生产，而新兴的合约开发和生产伙伴关係正在降低中小型生物技术公司的资本密集度。投资者的预期也在转变，资助者优先考虑具有明确生物标记策略和可生产性的项目，并越来越支持那些展现出扩充性和符合监管要求的平台。

最后，法规结构和支付方对话正在适应溶瘤疗法的独特属性。监管机构对创新终点和适应性试验方案持开放态度，前提是这些方案有强有力的机制论证和安全性资料支持。这些变革正在创造一种环境，在这种环境中，科学创新必须与成熟的营运和策略性的临床协调相结合，才能实现持续的商业性和患者效益。

评估2025年美国关税和贸易政策的预期变化将如何影响肿瘤治疗供应链、生产决策和合作模式

预计2025年的关税和贸易政策调整可能会对供应链、试剂采购和生物製药生产成本结构产生连锁反应，对裂解病毒研发企业及其合作伙伴造成重大影响。病毒载体生产所需的许多关键材料（例如试剂、特殊塑胶、一次性生物反应器零件以及某些上游细胞培养基成分）均依赖全球采购。进口关税的提高、海关清关时间的延长以及边境检查的加强，都可能导致活性药物成分和生产耗材的采购前置作业时间延长和到岸成本增加。

此外，如果关税改变区域采购的相对吸引力，可能会加速生产回流和近岸外包策略，促使申办方重新评估其供应商组合，并投资于冗余采购以降低中断风险。这种转变可能导致短期至中期内资本配置转向本地生产能力和国内灌装服务。同时，契约製造组织（CMO）可能会将更高的投入成本转嫁给客户，这可能会影响专案预算和临床试验启动时间。如果关税驱动的供应链变更需要更改供应商资格要求或原材料来源证明文件，则监管合规负担也可能受到影响，这可能需要对生物製药製剂进行额外的可比性评估。

贸易政策的改变也将影响共同研究模式。基于生物材料和分析服务快速交换的跨境学伙伴关係，若有新的海关和许可要求，可能会面临行政方面的阻碍。这些限制将延缓转化研究的进程，从而凸显数位化/远端合作、In Silico模拟和本地临床试验能力的重要性。最后，关税变化带来的累积影响将对采购能力有限的早期研发公司和学术新创公司造成特别沉重的打击，因此，策略性采购规划和供应商多元化对于确保专案韧性至关重要。

一种基于精确细分的观点适应症生物学、病毒平台属性、给药途径和临床护理环境与可操作的开发策略联繫起来。

基于细分的洞察揭示了每种适应症、病毒平台、给药途径和最终用户所面临的细微机会和限制，从而影响临床策略和商业规划。就癌症适应症而言，由于血脑障壁和肿瘤局部异质性，胶质母细胞瘤的给药面临独特的挑战。头颈癌的肿瘤内注射部位相对容易接近，但其免疫微环境复杂。此外，黑色素瘤仍然是典型的适应症模型，其皮肤病变便于直接给药和评估溶瘤活性。就病毒种类而言，基因工程病毒具有可工程化有效载荷和安全开关的优势，而野生型病毒则具有固有的组织亲和性并降低了初始开发的复杂性。在基因工程平台中，腺病毒、单纯疱疹病毒和痘苗病毒各自具有不同的组织亲和性、有效载荷能力和安全性特征，必须根据适应症的特定生物学特性进行客製化。

肿瘤内注射与静脉注射途径的选择对研究设计、病患选择及生产规范有重要影响。肿瘤内注射可实现较高的局部病毒滴度并降低全身暴露，但其应用仅限于易于触及的病灶。另一方面，静脉注射具有治疗转移性疾病的潜力，但面临全身中和、脱靶滞留和生物分布改变等挑战。终端用户（医院、研究机构和专科诊所）的细分影响商业性准入途径和服务提供模式。医院和肿瘤专科中心可提供肿瘤内治疗的综合医疗和先进介入治疗能力；研究机构可促进早期转化研究和研究者主导的临床试验；专科诊所可在门诊环境中支持常规给药流程和病患监测。

综上所述，这些细分因素凸显了病毒载体平台选择、有效载荷设计和递送策略与每种适应症和医疗环境的生物学和操作实际情况相符的重要性。策略决策必须平衡生物学原理与实际限制，以优化从临床检验到可扩展临床应用的路径。

全面、区域性地分析法规结构、临床基础设施和生产能力将如何影响全球主要市场中致癌病毒疗法的发展

区域趋势在全球溶瘤病毒领域的临床试验生态系统、製造地和监管合作中发挥核心作用。美洲地区受益于成熟的监管路径、广泛的临床试验网络以及丰富的风险投资和企业投资，但同时也面临着激烈的生产能力竞争和复杂的报销环境，这影响了其商业化策略。在欧洲、中东和非洲地区，各国卫生技术评估（HTA）框架和临床基础设施的差异造就了不同的监管环境，因此需要针对每个市场制定量身定制的监管措施和市场进入策略。同时，泛欧合作临床试验倡议和成熟的学术研究中心仍然是该地区实用化科学发展的重要驱动力。

在亚太地区，临床试验能力的快速提升、生物技术投资的不断增长以及政府对生物技术基础设施的战略支持，为加速临床开发和扩大本地生产创造了有利条件。患者群体、主要癌症适应症和治疗模式的区域差异，使得制定有针对性的临床开发策略势在必行。随着申办方权衡在靠近市场生产的优势与关税和物流方面的考量，区域製造地的重要性也日益凸显。跨区域伙伴关係和本地化的监管策略对于应对试验终点、数据要求和核准时间方面的差异至关重要。

因此，区域性见解不仅应该指导试验施行地点的选择，还应该指导如何协调生产、监管规划和商业策略，以最大限度地提高患者在不同医疗保健系统中的可及性和项目的韧性。

透过策略性企业行动、伙伴关係模式和生产製造投资，建立竞争优势，并实现溶瘤病毒计画的规模实施。

在溶瘤病毒领域营运的公司正透过平台专业化、策略联盟以及对生产规模化和监管准备的投资来实现差异化竞争。专注于模组化设计方法的公司能够实现有效载荷的快速更换，并简化跨多种肿瘤类型的临床转化；而另一些公司则专注于深度生物学优化，透过递送途径或肿瘤微环境特征来驱动特定适应症的溶瘤活性。早期研发公司与成熟的生物製药生产商之间的策略联盟日益普遍，这使得前者无需完全垂直整合即可获得符合GMP标准的生产能力、监管专业知识和商业管道。

投资趋势还表明，优先考虑明确的生物标记开发项目和转化数据的公司更有可能吸引寻求联合治疗机会的合作伙伴的策略关注。合约开发和生产组织 (CDMO) 透过将病毒载体特异性製程开发、分析验证和病毒特异性比较评估纳入其服务范围，降低了小型公司进入临床生产的门槛。此外，许可和共同开发契约通常包含与临床验证点挂钩的分级里程碑条款，这反映了风险分担和奖励加速开发之间的合理平衡。

从竞争角度来看，能够展现强大供应链策略、检验的生产平台以及积极主动的监管沟通能力的公司，将更有能力开展复杂的联合用药试验，并确保永续的商业化路径。在科学知识和营运需求快速发展的领域，组织能否灵活应对临床洞察并迅速调整平台应用，仍是一项核心竞争优势。

决策者的策略指南，整合了转化科学、生产弹性、监管沟通和市场进入规划，以降低专案推进风险。

产业领导者应制定一套整合科学策略、营运准备和市场进入规划的行动方案，以最大限度地提高转换和商业性成功的可能性。他们应优先开发稳健的生物标记和转化项目，以降低临床假设的风险，实现适应性研究设计，并支持与监管机构的沟通。同时，他们应儘早投资于製程开发和供应商选择，以确保可比性并最大限度地减少规模化生产过程中的延误。在条件允许的情况下，他们应与免疫肿瘤领域的合作伙伴进行策略合作，设计合理的联合治疗试验，利用互补的作用机制，并共用监管和商业风险。

在营运方面，我们将建立冗余供应链，并与多家合格供应商和契约製造建立合作关係，以减少海关和物流方面的影响。我们将根据适应症和地区实际情况调整临床开发路径，选择能够最大限度地提高讯号检测和患者入组可行性的给药途径和终点指标。我们将儘早与支付方和卫生技术评估机构接洽，了解他们对证据的期望，并设计卫生经济学资料收集方法，以支持未来的报销讨论。最后，我们将与监管机构保持积极对话，明确他们对安全性监测、生产可比性以及在适当情况下加快核准途径的期望，从而将科学进步转化为持续的患者用药。

透明的多学科研究，结合文献综述、专家咨询和情境分析，以检验策略洞察和营运建议。

本分析的调查方法包括对同行评审文献、监管指导文件、临床试验註册库和已发表的技术白皮书进行严格审查，以全面了解科学进展和营运趋势。此外，与临床医生、生物製程工程师、法规事务专业人员和契约製造主管进行的结构化专家咨询，为供应策略、规模化挑战和供应链脆弱性提供了切实可行的见解。证据综合分析优先考虑现有的原始信息，纳入监管申报文件，并透过独立专家意见和技术文件的三角验证来协调相互衝突的数据。

分析方法包括对转化挑战进行定性主题分析、透过营运差距分析来识别製造和物流瓶颈，以及基于情境评估政策对供应链和合作模式的影响。在临床数据的选择和解读过程中，我们遵循了伦理标准，特别关注安全性讯号、患者族群的异质性以及终点的有效性。最后，我们对建议进行了压力测试，以检验其在实际营运限制下的可行性，确保提案的措施在典型的开发週期和资源视窗内能够有效实施。

本文简明扼要地概述了溶瘤病毒研究的科学前景、操作要务以及将溶瘤病毒研究转化为有意义的临床应用所需的合作途径。

溶瘤病毒疗法在广阔的免疫肿瘤学领域占据着极具吸引力的地位，它兼顾了创新的生物学机制和特定的操作挑战。儘管科学已经发展到可以实现更精准的病毒设计和药物递送，但要将其转化为临床和商业性的成功，仍需在生产製造、供应链韧性和监管策略方面进行周密的协调。根据适应症、病毒平台、给药途径和最终用户环境进行策略性细分，可以指南有针对性的临床开发和商业化路径，从而提高患者获益和企业投资回报率。

政策制定者和行业相关人员必须持续关注贸易政策和区域製造业趋势等可能影响专案进度和成本结构的外部因素。透过采用结合科学严谨性和营运前瞻性的综合开发策略，各机构将能够更好地克服将溶瘤疗法从概念转化为临床应用过程中固有的复杂性。学术机构、产业合作伙伴、契约製造和监管机构之间的持续合作对于充分发挥溶瘤疗法在治疗难治性癌症患者方面的潜力至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将双特异性抗体和细胞激素有效载荷递送至肿瘤病毒以增强肿瘤免疫活化的进展
  • 整合合成生物学技术，改造溶瘤病毒，使其能可控复製并特异性裂解肿瘤细胞。
  • 溶瘤病毒与PD-1查核点抑制剂合併治疗固体癌的临床试验成功，提高了治疗反应率。
  • 开发系统性递送平台和奈米製剂以克服溶瘤病毒疗法中的中和抗体
  • 利用基于生物标记的患者选择策略和肿瘤分子谱分析优化溶瘤病毒的疗效
  • 透过监管路径协调和加速核准计划，加速溶瘤病毒疗法的商业化进程
  • 生物技术公司与学术机构伙伴关係，推动基于肿瘤抗原库的个人化肿瘤病毒平台的发展
  • 利用连续生物製程进行生产规模化创新，以经济高效的方式生产临床级溶瘤病毒

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 以癌症适应症分類的溶瘤病毒疗法市场

  • 胶质母细胞瘤
  • 头颈癌
  • 黑色素瘤

9. 依病毒类型分類的溶瘤病毒疗法市场

  • 基因改造病毒
    • 腺病毒
    • 单纯疱疹病毒
    • 牛痘病毒
  • 野生型病毒

10. 溶瘤病毒疗法市场依给药途径划分

  • 瘤内给药
  • 静脉注射

第十一章 溶瘤病毒疗法市场（以最终用户划分）

  • 医院
  • 研究所
  • 专科诊所

12. 各地区溶瘤病毒疗法市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 溶瘤病毒疗法市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国溶瘤病毒疗法市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Amgen Inc.
    • Merck & Co., Inc.
    • Replimune Group, Inc.
    • Oncolytics Biotech Inc.
    • Sorrento Therapeutics, Inc.
    • Transgene SA
    • PsiOxus Therapeutics Ltd
    • OncoSec Medical Incorporated
    • Targovax ASA
    • SillaJen, Inc.
Product Code: MRR-007C484E5E64

The Oncolytic Virus Therapies Market is projected to grow by USD 444.83 million at a CAGR of 16.34% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 132.50 million
Estimated Year [2025] USD 153.79 million
Forecast Year [2032] USD 444.83 million
CAGR (%) 16.34%

A strategic framing of oncolytic virus therapies highlighting translational promise, manufacturing realities, clinical design imperatives and ecosystem enablers

Oncolytic virus therapies represent a rapidly evolving intersection of virology, immuno-oncology, and precision medicine, offering a novel mechanism of action that selectively infects and lyses tumor cells while stimulating antitumor immunity. The field has matured from proof-of-concept clinical demonstrations to more sophisticated engineering of viral genomes, payloads, and delivery systems that aim to broaden therapeutic windows and address solid tumor accessibility challenges. As development pathways advance, stakeholders must reconcile biological complexity with practical considerations such as scalable manufacturing, cold-chain logistics, and the necessity of robust clinical endpoints that capture both direct oncolytic effects and downstream immune-mediated responses.

Translational success often hinges on the integration of preclinical mechanistic insight with pragmatic trial design. Iterative learning from early-phase studies has refined patient selection strategies, intratumoral and systemic dosing approaches, and combinatorial regimens with checkpoint inhibitors or other immunomodulators. Continued progress requires tight alignment between scientific innovation and regulatory engagement to establish meaningful safety monitoring frameworks and to validate biomarkers that predict response or resistance. Moreover, public and private research institutions, clinical trial networks, and specialized contract manufacturing organizations are forming the operational backbone that will determine the pace at which promising candidates can move from bench to larger cohort evaluation.

Looking forward, the trajectory of oncolytic virus therapies will depend not only on scientific breakthroughs but on the ecosystem's ability to scale manufacturing, secure supply chains for viral vectors and raw materials, and navigate evolving reimbursement and policy environments. Stakeholders that proactively address these translational and operational imperatives will be better positioned to convert biological potential into clinically actionable therapeutics.

How recent technological advances, combination therapy strategies, manufacturing improvements, and regulatory evolutions are redefining oncolytic virus development and commercialization

The landscape for oncolytic virus therapies is shifting in ways that reconfigure competitive dynamics, clinical development strategies, and investment priorities. Advances in viral engineering now enable the incorporation of payloads that modulate tumor microenvironments, express immune-stimulatory cytokines, or present tumor-associated antigens to enhance antigen spreading. These technological shifts are complemented by improved vector design to enhance tumor selectivity and to limit off-target tropism, thereby improving therapeutic indices and expanding potential indications beyond accessible superficial lesions.

Concurrently, clinical strategy is evolving from monotherapy proofs toward combination regimens where oncolytic agents act synergistically with immune checkpoint inhibitors, adoptive cell therapies, or targeted agents. This shift requires more complex trial designs and collaborative networks to test rational combinations and dose sequencing. On the operations side, improvements in GMP-compliant manufacturing and fill-finish processes are enabling higher-quality and more reproducible viral product batches, while emerging contract development and manufacturing partnerships are offloading capital intensity from smaller biotechs. Investor expectations are also changing: funders increasingly prioritize programs with clear biomarker strategies and manufacturability, favoring platforms that demonstrate scalability and regulatory engagement.

Finally, regulatory frameworks and payor dialogues are adapting to the unique attributes of oncolytic modalities, with agencies showing openness to innovative endpoints and adaptive trial schemas when supported by strong mechanistic rationale and safety data. Taken together, these transformative shifts are creating an environment where scientific novelty must be matched by operational maturity and strategic clinical collaborations to achieve durable commercial and patient impact.

Assessing how anticipated United States tariffs and trade policy shifts in 2025 could reshape supply chains, manufacturing decisions, and collaborative models for oncolytic therapies

Anticipated tariff measures and trade policy adjustments in 2025 are likely to have ripple effects on supply chains, reagent sourcing, and the cost structures of biologics manufacturing that materially influence oncolytic virus developers and their partners. Many critical inputs for viral vector production-including reagents, specialized plastics, single-use bioreactor components, and certain upstream cell culture media constituents-are sourced globally; any increase in import duties, customs processing times, or border checks can translate into longer lead times and higher landed costs for active pharmaceutical ingredients and manufacturing supplies.

Moreover, tariffs that alter the relative attractiveness of regional sourcing may accelerate reshoring or near-shoring strategies, prompting sponsors to reassess supplier portfolios and invest in redundant sourcing to mitigate disruption risk. This change can lead to short- and medium-term capital allocation toward local manufacturing capacity or in-country fill-finish services. In parallel, contract manufacturing organizations may pass through higher input costs to clients, affecting program budgets and potentially the timing of trial initiation. Regulatory compliance burdens can also be affected if tariff-driven supply chain modifications necessitate changes in supplier qualifications or material provenance documentation, requiring additional comparability assessments for biologics.

Trade policy shifts can also influence collaborative models. Cross-border academic-industry partnerships that rely on rapid exchange of biological materials and analytical services may face administrative friction if new customs or licensing requirements are introduced. Such constraints can slow translational timelines and raise the value of digital and remote collaborations, in silico modeling, and local clinical trial capacity. Finally, the cumulative impact of tariff changes will disproportionately affect early-stage developers and academic spin-outs with limited procurement scale, making strategic procurement planning and supplier diversification essential for program resilience.

Precision segmentation-driven perspectives that link indication biology, viral platform attributes, delivery routes, and clinical care settings to actionable development strategies

Segmentation-informed insights reveal nuanced opportunities and constraints across indications, viral platforms, administration routes, and end users that influence clinical strategy and commercial planning. When considering cancer indications, glioblastoma presents unique delivery challenges due to the blood-brain barrier and localized tumor heterogeneity, head and neck cancers offer relatively accessible intratumoral injection sites with complex immune microenvironments, and melanoma continues to serve as a model indication where cutaneous lesions facilitate direct administration and oncolytic activity assessment. In terms of virus type, genetically modified viruses bring the advantage of engineered payloads and safety switches, while wild type viruses can offer innate tropism and lower initial development complexity; within genetically modified platforms, adenovirus, herpes simplex virus, and vaccinia virus each offer distinct tissue tropisms, payload capacities, and safety profiles that must be aligned to indication-specific biology.

Administration route choices between intratumoral and intravenous approaches materially impact trial design, patient selection, and manufacturing specifications. Intratumoral administration enables high local viral titers and reduced systemic exposure but limits applicability to accessible lesions, whereas intravenous delivery offers the potential for treating disseminated disease but faces challenges of systemic neutralization, off-target sequestration, and altered biodistribution. End-user segmentation across hospitals, research institutes, and specialty clinics shapes commercial access pathways and service delivery models. Hospitals and specialized oncology centers offer integrated care and advanced interventional capabilities for intratumoral procedures, research institutes drive early translational studies and investigator-initiated trials, and specialty clinics can support routine administration workflows and patient monitoring for outpatient regimens.

Taken together, these segmentation elements underscore the importance of aligning viral platform selection, payload engineering, and delivery strategy to the biological and operational realities of each indication and care setting. Strategic decisions must balance the biological rationale with practical implementation constraints to optimize the pathway from clinical validation to scalable clinical use.

A comprehensive regional lens exploring how regulatory frameworks, clinical infrastructure, and manufacturing capabilities influence oncolytic therapy development across major global markets

Regional dynamics play a central role in shaping clinical trial ecosystems, manufacturing footprints, and regulatory interactions across the global oncolytic virus landscape. The Americas benefit from established regulatory pathways, extensive clinical trial networks, and deep venture and corporate investment but also face concentrated competition for manufacturing capacity and complex reimbursement environments that influence commercialization strategies. Europe, Middle East & Africa present diverse regulatory landscapes where country-specific health technology assessment frameworks and clinical infrastructure variability drive tailored regulatory and market-access approaches; collaborative pan-European trial initiatives and well-established academic centers continue to be important contributors to translational science in the region.

In Asia-Pacific, rapidly expanding clinical trial capacity, increasing biotech investment, and strategic government support for biotechnology infrastructure create fertile conditions for accelerated clinical development and local manufacturing expansion. Differences in patient demographics, prevalent cancer indications, and treatment paradigms across regions necessitate targeted clinical development strategies, and regional manufacturing hubs are becoming increasingly relevant as sponsors weigh the benefits of near-market production against tariff and logistics considerations. Cross-regional partnerships and localized regulatory engagement strategies are instrumental in navigating differences in trial endpoints, data requirements, and approval timelines.

Therefore, regional insight should inform not only where trials are conducted but how manufacturing, regulatory planning, and commercial strategies are orchestrated to maximize patient access and program resilience across disparate healthcare systems.

Strategic corporate behaviors, partnership models, and manufacturing investments that define competitive advantage and enable scalable oncolytic virus program execution

Companies operating in the oncolytic virus sector are differentiating through platform specialization, strategic collaborations, and investments in manufacturing scale-up and regulatory engagement. Some organizations are focusing on modular engineering approaches that enable rapid payload swaps and streamlined clinical translation across multiple tumor types, while others emphasize deep biological optimization for specific indications where delivery routes and tumor microenvironment characteristics favor oncolytic activity. Strategic collaborations between early-stage developers and established biologics manufacturers have become commonplace, facilitating access to GMP capacity, regulatory expertise, and commercial channels without necessitating full in-house vertical integration.

Investment patterns also show that firms prioritizing clear biomarker development programs and translational data tend to attract more strategic interest from partners seeking combination therapy opportunities. Contract development and manufacturing organizations are evolving their service offerings to include viral vector-specific process development, analytical method validation, and virus-specific comparability assessments, thereby lowering the barrier to clinical manufacturing for smaller companies. Additionally, licensing deals and codevelopment agreements frequently include provisions for phased milestones tied to clinical proof points, reflecting a pragmatic balance between risk-sharing and incentivizing accelerated development.

From a competitive perspective, companies that can demonstrate robust supply chain strategies, validated manufacturing platforms, and proactive regulatory interactions will be preferentially positioned to execute complex combination trials and to secure sustainable commercial pathways. Organizational agility in responding to clinical learnings and in pivoting platform applications remains a core differentiator in a field where scientific understanding and operational demands evolve rapidly.

An integrated strategic playbook for decision-makers that aligns translational science, manufacturing resilience, regulatory engagement, and market access planning to de-risk program progression

Industry leaders should adopt an integrated playbook that aligns scientific strategy with operational readiness and market access planning to maximize the probability of translational and commercial success. Prioritize the development of robust biomarker and translational programs that can de-risk clinical hypotheses, enable adaptive trial designs, and support regulatory discussions; simultaneously, invest early in process development and vendor qualification to ensure comparability and minimize delays during scale-up. Where feasible, pursue strategic collaborations with immuno-oncology partners to design rational combination studies that leverage complementary mechanisms and to share regulatory and commercialization risk.

Operationally, build redundant supply chains and establish relationships with multiple qualified suppliers and contract manufacturers to mitigate tariff-related and logistical disruptions. Tailor clinical development pathways to indication- and region-specific realities, selecting administration routes and endpoints that optimize signal detection and patient enrollment feasibility. Engage payors and health technology assessment bodies early to understand evidence expectations and to design health-economic data collection approaches that support future reimbursement discussions. Finally, maintain active regulatory dialogue to clarify expectations around safety monitoring, manufacturing comparability, and accelerated approval pathways where appropriate, translating scientific momentum into durable patient access.

A transparent, multidisciplinary research framework combining literature synthesis, expert consultations, and scenario analysis to validate strategic insights and operational recommendations

The research methodology underpinning this analysis combined a rigorous review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available technical white papers to construct a holistic view of scientific progress and operational trends. In addition, structured expert consultations with clinicians, bioprocess engineers, regulatory affairs specialists, and contract manufacturing executives informed practical considerations around delivery strategies, scale-up challenges, and supply chain vulnerabilities. Evidence synthesis prioritized primary sources and regulatory filings where available, and conflicting data points were reconciled through triangulation across independent expert perspectives and technical documentation.

Analytical approaches included qualitative thematic analysis of translational challenges, operational gap mapping to identify bottlenecks in manufacturing and logistics, and scenario-based assessment of policy impacts on supply chains and collaborative models. Ethical standards guided the selection and interpretation of clinical data, with careful attention paid to safety signals, patient population heterogeneity, and endpoint relevance. Finally, recommendations were stress-tested against real-world operational constraints to ensure that proposed actions are implementable within typical development timelines and resource envelopes.

A concise synthesis emphasizing the scientific promise, operational imperatives, and collaborative pathways necessary to translate oncolytic virus research into meaningful clinical impact

Oncolytic virus therapies occupy a compelling niche within the broader immuno-oncology landscape, balancing innovative biological mechanisms with tangible operational challenges. The science has progressed to enable more precise viral engineering and payload delivery, but translation to clinical and commercial success requires careful orchestration of manufacturing, supply chain resilience, and regulatory strategy. Strategic segmentation by indication, virus platform, administration route, and end-user setting informs targeted clinical development and commercialization pathways that improve the likelihood of patient benefit and organizational return on investment.

Policymakers and industry stakeholders must remain attentive to external factors such as trade policy and regional manufacturing dynamics that can influence program timelines and cost structures. By adopting integrated development strategies that pair scientific rigor with operational foresight, organizations can better navigate the complexity inherent in bringing oncolytic therapies from concept to clinic. Continued collaboration across academic centers, industry partners, contract manufacturers, and regulators will be essential to realize the full potential of oncolytic modalities for patients with hard-to-treat cancers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in arming oncolytic viruses with bispecific antibodies and cytokine payloads for enhanced tumor immune activation
  • 5.2. Integration of synthetic biology techniques for controllable replication and tumor-specific lysis in oncolytic virus design
  • 5.3. Clinical trial successes combining oncolytic viruses with PD-1 checkpoint inhibitors to improve response rates in solid tumors
  • 5.4. Development of systemic delivery platforms and nanoformulations to overcome neutralizing antibodies in oncolytic virotherapy
  • 5.5. Adoption of biomarker-driven patient selection strategies using tumor molecular profiling to optimize oncolytic virus efficacy
  • 5.6. Regulatory pathway harmonization efforts and expedited approval programs accelerating oncolytic viral therapy commercialization
  • 5.7. Collaborative partnerships between biotech companies and academic centers to advance personalized oncolytic virus platforms based on tumor antigen repertoires
  • 5.8. Manufacturing scale-up innovations leveraging continuous bioprocessing for cost-effective production of clinical-grade oncolytic viruses

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncolytic Virus Therapies Market, by Cancer Indication

  • 8.1. Glioblastoma
  • 8.2. Head And Neck Cancer
  • 8.3. Melanoma

9. Oncolytic Virus Therapies Market, by Virus Type

  • 9.1. Genetically Modified Virus
    • 9.1.1. Adenovirus
    • 9.1.2. Herpes Simplex Virus
    • 9.1.3. Vaccinia Virus
  • 9.2. Wild Type Virus

10. Oncolytic Virus Therapies Market, by Administration Route

  • 10.1. Intratumoral
  • 10.2. Intravenous

11. Oncolytic Virus Therapies Market, by End User

  • 11.1. Hospitals
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. Oncolytic Virus Therapies Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oncolytic Virus Therapies Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oncolytic Virus Therapies Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Amgen Inc.
    • 15.3.2. Merck & Co., Inc.
    • 15.3.3. Replimune Group, Inc.
    • 15.3.4. Oncolytics Biotech Inc.
    • 15.3.5. Sorrento Therapeutics, Inc.
    • 15.3.6. Transgene SA
    • 15.3.7. PsiOxus Therapeutics Ltd
    • 15.3.8. OncoSec Medical Incorporated
    • 15.3.9. Targovax ASA
    • 15.3.10. SillaJen, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ONCOLYTIC VIRUS THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 97. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 99. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 110. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 114. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 122. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 170. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 175. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 176. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 177. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 197. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 200. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 201. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 202. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 203. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 208. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 209. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 212. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 213. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 214. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 215. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 232. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 233. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 236. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 237. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 238. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 239. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 244. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 245. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 248. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 249. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 250. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 251. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 260. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 261. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 262. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 263. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 273. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 275. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 278. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 279. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 282. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 283. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 284. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 285. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 288. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 289. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 292. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 293. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 294. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 295. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 298. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 299. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 302. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 303. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 304. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 305. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 308. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2032 (USD MILLION)
  • TABLE 309. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 312. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2032 (U